Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02939183 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT02939183 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 61 participants.
The verdict
NCT02939183, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in participants with relapsed refractory multiple myeloma.
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Immediate Release (IR) Formulation
- DRUG Gastro-Retentive (GR) Formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2017-01-17 |
| Est. Completion | 2022-10-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02939183
The ClinicalTrials.gov registry entry for NCT02939183 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT02939183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02939183 about?
NCT02939183 is a clinical study titled "Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma". A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in participants with relapsed refractory multiple myeloma.
What is the current status of trial NCT02939183?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2017-01-17. Estimated completion is 2022-10-06.
What interventions are being tested in trial NCT02939183?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Immediate Release (IR) Formulation (DRUG), Gastro-Retentive (GR) Formulation (DRUG).
Who is sponsoring clinical trial NCT02939183?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.